Patient characteristics
| . | n (%) . | P . | |
|---|---|---|---|
| GOYA (n = 552) . | MAIN (n = 225) . | ||
| Age, y | .061 | ||
| Median | 63 | 62 | |
| Range | 18-86 | 21-79 | |
| Male sex | 288 (52.2) | 107 (47.6) | .268 |
| Region | <.001* | ||
| Western Europe | 216 (39.1) | 91 (40.4) | |
| Eastern Europe | 122 (22.1) | 59 (26.2) | |
| North America | 93 (16.8) | 17 (7.6) | |
| Asia | 89 (16.1) | 13 (5.8) | |
| Other | 32 (5.8) | 45 (18.2) | |
| IPI | .0057† | ||
| Low | 107 (19.4) | 28 (12.5) | |
| Low-intermediate | 194 (35.1) | 102 (45.3) | |
| High-intermediate | 161 (29.2) | 71 (31.6) | |
| High | 90 (16.3) | 24 (10.7) | |
| ECOG PS | <.001 | ||
| 0-1 | 490 (88.8) | 164 (73.9) | |
| 2-3 | 62 (11.2) | 58 (26.1) | |
| Ann Arbor stage | n = 223 | .204 | |
| I and II | 134 (24.3) | 64 (28.7) | |
| III and IV | 418 (75.8) | 159 (71.3) | |
| Extranodal involvement | 364 (65.9) | 100 (44.4) | <.001 |
| COO | .184 | ||
| GCB | 298 (55.4) | 70 (47.9) | |
| ABC | 151 (28.1) | 52 (35.6) | |
| Unclassified | 89 (16.5) | 24 (16.4) | |
| Median follow-up, mo | 29.9 | 24.2 | <.001 |
| . | n (%) . | P . | |
|---|---|---|---|
| GOYA (n = 552) . | MAIN (n = 225) . | ||
| Age, y | .061 | ||
| Median | 63 | 62 | |
| Range | 18-86 | 21-79 | |
| Male sex | 288 (52.2) | 107 (47.6) | .268 |
| Region | <.001* | ||
| Western Europe | 216 (39.1) | 91 (40.4) | |
| Eastern Europe | 122 (22.1) | 59 (26.2) | |
| North America | 93 (16.8) | 17 (7.6) | |
| Asia | 89 (16.1) | 13 (5.8) | |
| Other | 32 (5.8) | 45 (18.2) | |
| IPI | .0057† | ||
| Low | 107 (19.4) | 28 (12.5) | |
| Low-intermediate | 194 (35.1) | 102 (45.3) | |
| High-intermediate | 161 (29.2) | 71 (31.6) | |
| High | 90 (16.3) | 24 (10.7) | |
| ECOG PS | <.001 | ||
| 0-1 | 490 (88.8) | 164 (73.9) | |
| 2-3 | 62 (11.2) | 58 (26.1) | |
| Ann Arbor stage | n = 223 | .204 | |
| I and II | 134 (24.3) | 64 (28.7) | |
| III and IV | 418 (75.8) | 159 (71.3) | |
| Extranodal involvement | 364 (65.9) | 100 (44.4) | <.001 |
| COO | .184 | ||
| GCB | 298 (55.4) | 70 (47.9) | |
| ABC | 151 (28.1) | 52 (35.6) | |
| Unclassified | 89 (16.5) | 24 (16.4) | |
| Median follow-up, mo | 29.9 | 24.2 | <.001 |
COO, cell of origin; ECOG PS, Eastern Cooperative Oncology Group performance status.
Regional makeup significantly differed, with more South and Central American samples in MAIN (n = 41) vs GOYA (n = 13).
International Prognostic Index (IPI) groups differed significantly, with more intermediate samples in MAIN.